...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith trial partners

After rereading my previous post I have to make a correction in the last paragraph. 

A successful trial for RVX would give ZCC shareholders potentially $1.00 per QUARTER (not year) of royalties for 10 years or more.

My holding

tada

 

Share
New Message
Please login to post a reply